Meeting
2022 ASCO Annual Meeting
Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience.
Authors
Doris K. Hansen
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Doris K. Hansen , Surbhi Sidana , Lauren Peres , Leyla Shune , Douglas W. Sborov , Hamza Hashmi , Mehmet H. Kocoglu , Shebli Atrash , Gary Simmons , Nilesh Kalariya , Christopher J. Ferreri , Aimaz Afrough , Ankit J. Kansagra , Peter M. Voorhees , Melissa Alsina , Joseph McGuirk , Frederick L. Locke , Krina K. Patel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8042)
DOI
10.1200/JCO.2022.40.16_suppl.8042
Abstract #
8042
Poster Bd #
466
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM).
First Author: Doris K. Hansen
Poster
2022 ASCO Annual Meeting
Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI.
First Author: Saad Zafar Usmani
Poster
2021 ASCO Annual Meeting
Long-term follow-up results of a multicenter first-in-human study of the dual BCMA/CD19 Targeted FasT CAR-T GC012F for patients with relapsed/refractory multiple myeloma.
First Author: Hua Jiang
Poster
2021 ASCO Annual Meeting
Anakinra (AKR) prophylaxis (ppx) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving orvacabtagene autoleucel (orva-cel).
First Author: Luciano J. Costa